Quality of life during adjuvant immunotherapy for locally advanced non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study follows adults with locally advanced NSCLC who are receiving concurrent chemoradiotherapy plus a year of immune checkpoint inhibitors. It aims to document self-reported health and quality of life during treatment, recognizing that immunotherapy can cause unique and late-appearing side effects. Data are collected at two specialized oncology centers in Sweden to understand how patients endure this additional therapy and what factors influence well-being. The results may guide supportive care and inform future patient management during adjuvant immunotherapy. No experimental interventions are being tested in this design; the focus is on observation of real-world experiences and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with locally advanced non-small lung cancer
* cared for at either one of two specialized oncology centres
* ≥ 18 years of age
* planned for concurrent chemoradiotherapy including ICI for 12 months
* performance status 0-2.

Exclusion Criteria:

* diseases or comorbidities that may have significant impact on the outcome variables
* limited understanding of the Swedish language preventing the possibility to give oral and written informed consent.

Where it's running

• Department of Oncology, Sahlgrenska University Hospital
  Gothenburg, Sweden Recruiting

Study contacts

• Study coordinator: Sofie Jakobsson, Associated professor
• Email: sofie.jakobsson@fhs.gu.se
• Phone: +46766182858

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term survival and AI-based prediction in NSCLC patients treated with immunotherapy

  This study tests whether AI analysis of routine pathology images, along with multi-omics data, can predict long-term survival for people with advanced NSCLC treated with immunotherapy.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07668037

• Cardiorespiratory exercise testing before and during lung cancer treatment

  This project tests whether a supervised exercise test (CPET) can measure heart and lung fitness in adults with lung cancer who are able to exercise (WHO/ECOG 0-2) before and during their treatment.

  Recruiting Medical University of Bialystok · Bialystok, Podlaskie Voivodeship · NCT07529145

• Fiber-Boost: High-fiber diet with immunotherapy for advanced non-small cell lung cancer

  This trial will test whether adding a high-fiber diet to first-line immunotherapy helps adults with advanced non-small cell lung cancer and how it changes the gut bacteria and immune response.

  Recruiting Cantonal Hospital of St. Gallen · Basel and 3 other locations · NCT07483112

• Amivantamab with Lazertinib or Chemotherapy before surgery in EGFR-mutated NSCLC

  This study tests whether giving amivantamab together with lazertinib or with carboplatin and pemetrexed before surgery can slow or stop tumor growth in people with resectable EGFR-mutated NSCLC.

  Recruiting at 27 sites Phase 2 Janssen Research & Development, LLC · Duarte, California and 26 other locations · NCT07586202

• Multidisciplinary treatment planning for older people with lung cancer

  We will test a team-based approach that uses geriatric assessments to create personalized treatment plans for people aged 60–90 with newly diagnosed lung cancer to see if it improves 3-year progression-free survival compared with past patients.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07509333

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.